

CADTH

Lecture Series

acmts.ca |  @acmts_cadth
#CADTHTalks

CADTH Evidence
Driven.

Using Patient Perspectives to Frame HTAs

SARAH BERGLAS

PATIENT ENGAGEMENT OFFICER, CADTH

APRIL 2015


CADTH



Canadian Drug Expert Committee (CDEC) reflects



CADTH




What is the value of the new drug, as compared to existing options?



Patient important outcomes are included in CADTH's protocol

Methodology



Repeated x30 sequential CDR reviews

Drug	Indication
Dificid	<i>C. difficile</i> infection
Xiaflex	Dupuytren's contracture
Eliquis	Stroke prevention
Kalydeco	Cystic fibrosis
Esbriet	Pulmonary fibrosis
Aloxi	Chemo nausea
Orencia	RA
Seebri	COPD
Stribild	HIV
Soliris	aHUS
Bystolic	Hypertension
Humira	Juvenile arthritis
Tecfidera	MS
Sublinox	Insomnia
Afinitor	Tuberous sclerosis

Drug	Indication
Fycompa	Epilepsy
Edarbi	Hypertension
Edarbyclor	Hypertension
Fibristal	Uterine fibroids
Picato	Actinic keratosis
Latuda	Schizophrenia
Genotropin	Growth hormone deficiency
Jetrea	Vitromacular adhesion
Simponi	Ulcerative colitis
Inspra	Heart failure
Actemra	Juvenile arthritis
Neupro	Parkinson's disease
Botox	Chronic migraine
Tudorza Genuair	COPD
Galexos	Hepatitis C

Final recommendations published March 2013 – June 2014

**HEALTH-RELATED
QUALITY OF LIFE**

AVOID HOSPITALIZATION

EASE OF ADHERENCE

AVOID FURTHER DISEASE

**FEWER SIDE EFFECTS
OF TREATMENT**

COST
TREATMENT DURATION

ALTERNATIVE TREATMENT

**SYMPTOM
RELIEF**


LONGER
LIFE

FEWER TREATMENT SUPPORTS

TARGET ROOT CAUSE

INDEPENDENCE
**PSYCHOSOCIAL
QUALITY
OF LIFE**

Results



FEAR

EMBARASSMENT

DEPENDENCY

GUILT

CADTH Evidence
Driven.

CADTH

Lecture Series

acmts.ca |  @acmts_cadth
#CADTHTalks

CADTH Evidence
Driven.